SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets closed

Sanofi (SNY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
40.02+0.30 (+0.76%)
At close: 4:02 PM EST
People also watch:
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close39.72
Open39.66
Bid39.75 x 300
Ask41.49 x 500
Day's Range39.57 - 40.33
52 Week Range36.81 - 44.50
Volume1,472,714
Avg. Volume2,582,763
Market Cap107.74B
Beta0.80
PE Ratio (TTM)23.26
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.66 (4.19%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedia3 days ago

    Drugs Delayed By Regeneron, Sanofi Plant (REGN, SNY)

    Two potential blockbuster drugs being developed by Regeneron and Sanofi may be delayed by deficiencies at Sanofi's manufacturing plant in France.

  • PR Newswire3 days ago

    Mymetics Starts Research Project with Sanofi for Influenza Vaccines

    EPALINGES, Switzerland, Dec. 1, 2016 /PRNewswire/ -- Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics B.V. has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics' proprietary virosome technology platform in pre-clinical settings. "We are very excited to start this initial collaboration project with Sanofi, a world leader in the vaccine industry," said Ronald Kempers, CEO of Mymetics.

  • Sanofi SA (ADR) (SNY) Facing Manufacturing Headache On Two Blockbusters
    Insider Monkey4 days ago

    Sanofi SA (ADR) (SNY) Facing Manufacturing Headache On Two Blockbusters

    Manufacturing problems in France threaten to delay the release of Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s blockbuster drug, dupilumab, according to analysts at Leerink. The drug, which has already won priority review from the FDA for the treatment of eczema, now faces the risk of losing its PDUFA date slated for early […]